Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer

Status:
Completed

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

To determine the antitumor efficacy and the safety of SU-014813 at a dose of 100 mg orally once daily in patients with Metastatic Breast Cancer

Phase 2

Pfizer